Profil
Greg Mann is currently Head-Investors & Media at Kura Oncology, Inc. since 2025.
Former roles include Director-Investor Relations at Abgenix, Inc., Executive Director-IR & Corporate Communications at Kyntra Bio, Inc., Vice President-Investor Relations at Kite Pharma, Inc., and Media & Investor Relations Contact at Nkarta, Inc.
Postes actifs de Greg Mann
| Sociétés | Poste | Début |
|---|---|---|
| KURA ONCOLOGY, INC. | Investor Relations Contact | 01/07/2025 |
Anciens postes connus de Greg Mann
| Sociétés | Poste | Fin |
|---|---|---|
Abgenix, Inc.
Abgenix, Inc. BiotechnologyHealth Technology Develops therapeutic products | Investor Relations Contact | 01/01/2006 |
| NKARTA, INC. | Investor Relations Contact | - |
| KITE PHARMA INC | Investor Relations Contact | - |
| KYNTRA BIO, INC. | Investor Relations Contact | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Abgenix, Inc.
Abgenix, Inc. BiotechnologyHealth Technology Develops therapeutic products | Health Technology |
Kura Oncology, Inc.
Kura Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
FibroGen, Inc.
FibroGen, Inc. Pharmaceuticals: MajorHealth Technology Develops biotechnology-based drugs | Health Technology |
Kite Pharma, Inc.
Kite Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company which engages in the development of novel cancer immunotherapeutic products | Health Technology |
Nkarta, Inc.
Nkarta, Inc. BiotechnologyHealth Technology Discovers, develops and delivers NK cell therapies for cancer treatment | Health Technology |
















